This is the authors' abstract. We don't add key points for this paper.
Patients with renal cell carcinoma (RCC) often remain asymptomatic until the disease is advanced, with about 25% presenting at an advanced stage. We present a case of metastatic RCC treated with combination ipilimumab and nivolumab with complete radiological and pathological response. Currently, combination nivolumab and ipilimumab is a preferred option for intermediate- and poor-risk patients with clear cell stage IV RCC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: